ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1734

Apremilast Is Associated with Long-Term DAS-28 (CRP) Remission and Improvements in Skin Disease: Results from a Phase III Study in DMARD/Biologic-Experienced Active Psoriatic Arthritis Patients

Christopher J Edwards1, Francisco J Blanco2, Jeffrey J Crowley3, Melissa McIlraith4, Kamal Shah4, Nikolay Delev4, Lichen Teng4 and Charles A Birbara5, 1University Hospital Southampton, Southampton, United Kingdom, 2INIBIC-Hospital Universitario A Coruña, Galicia, Spain, 3Bakersfield Dermatology, Bakersfield, CA, 4Celgene Corporation, Summit, NJ, 5University of Massachusetts Medical School, Worcester, MA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Treatment goals for long-term control of skin and joint symptoms in active psoriatic arthritis (PsA) include clinically important changes in DAS-28 (CRP), achievement of remission in DAS-28 (CRP), reduction in swollen joint count (SJC), and decrease in skin disease.1 PALACE 3 (NCT01212770) included PsA patients (pts) with active joint disease and an active skin lesion at the time of enrollment. We report the impact of apremilast (APR) on PsA manifestations over 4 years.

Methods: Pts were stratified by baseline (BL) DMARD use (yes/no) and psoriasis involvement of the body surface area (<3%/≥3%) and randomized (1:1:1) to placebo (PBO), APR 30 mg BID (APR30), or APR 20 mg BID (APR20). After the 24-week PBO-controlled phase, all pts were treated with APR30 or APR20 and could enroll in the long-term extension. Efficacy assessments were conducted through Week 208.

Results: 505 pts were randomized and received ≥1 dose of study medication (PBO: n=169; APR30: n=167; APR20: n=169). A total of 91% (227/249) of pts starting the fourth year of APR therapy completed the Week 208 visit. Pts treated with APR30 demonstrated sustained decreases in disease activity at Week 208, as shown by mean change from BL in DAS-28 (CRP) of −1.66; 80.3% achieved good/moderate EULAR response and 50.4% achieved DAS-28 (CRP) remission. Sustained effect on inflammation at Week 208 was also demonstrated by mean/median percent changes in SJC, a marker of inflammatory activity, of −77.4%/−100.0% (Table); 64.8% of pts had an SJC 0 or 1. Decreases in disability and maintenance of functionality were shown by sustained improvements in Health Assessment Questionnaire-Disability Index (HAQ-DI) scores (Table). A continued effect on skin disease was shown by decreases in skin involvement, as measured by the Psoriasis Area and Severity Index (PASI); 54.7% of APR30 pts had BL PASI >5 and 27.3% had BL PASI >10; at Week 208, 64.5% had PASI <3 and 77.4% had PASI ≤5. PASI-75 and PASI-50 response rates also signified clinically significant relief (Table). In pts treated with APR20, similar findings were observed at Week 208. No new safety concerns were identified through 208 weeks of APR30 therapy. During Weeks >156 to ≤208 of APR30 exposure, the only AE occurring in ≥5% of pts was nasopharyngitis; most AEs were mild or moderate in severity. Serious AEs occurred in 7.2% of APR30 pts Weeks >156 to ≤208, similar to rates in earlier study periods. Few discontinuations due to AEs (0.7%) occurred over Weeks >156 to ≤208. The APR20 safety profile was similar to that of APR30.

Conclusion: Over 208 weeks, APR demonstrated sustained and clinically important improvements in PsA signs and symptoms, including physical function and associated psoriasis, among pts continuing the study. APR was generally well tolerated with an acceptable safety profile. Reference: 1. Gossec et al. Ann Rheum Dis. 2015 Dec 7. doi: 10.1136/annrheumdis-2015-208337.


Disclosure: C. J. Edwards, Celgene Corporation, Pfizer, Roche, Samsung, 2,Celgene Corporation, Pfizer, Roche, Samsung, 5,Abbott, GSK, Pfizer, Roche, 8; F. J. Blanco, Bioibérica, Gebro Pharma, Pfizer, 5; J. J. Crowley, AbbVie, Amgen, Celgene Corporation, Janssen, Merck, Pfizer, 2,AbbVie, Amgen, 5,AbbVie, 8; M. McIlraith, Celgene Corporation, 3; K. Shah, Celgene Corporation, 3; N. Delev, Celgene Corporation, 3; L. Teng, Celgene Corporation, 3; C. A. Birbara, Amgen, BMS, Incyte, Eli Lilly, Merck, Pfizer, 2.

To cite this abstract in AMA style:

Edwards CJ, Blanco FJ, Crowley JJ, McIlraith M, Shah K, Delev N, Teng L, Birbara CA. Apremilast Is Associated with Long-Term DAS-28 (CRP) Remission and Improvements in Skin Disease: Results from a Phase III Study in DMARD/Biologic-Experienced Active Psoriatic Arthritis Patients [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/apremilast-is-associated-with-long-term-das-28-crp-remission-and-improvements-in-skin-disease-results-from-a-phase-iii-study-in-dmardbiologic-experienced-active-psoriatic-arthritis-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/apremilast-is-associated-with-long-term-das-28-crp-remission-and-improvements-in-skin-disease-results-from-a-phase-iii-study-in-dmardbiologic-experienced-active-psoriatic-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology